^
Association details:
| Biomarker: | BRAF mutation + MAP2K1 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma
Excerpt:
We conducted a phase II trial in patients with melanoma whose tumors harbored a BRAF mutation. Patients were stratified by phosphorylated-AKT (pwith AKT) expression (high vs. low) and treated selumetinib 75 mg per os twice daily....Among the two nonresponding, low pAKT patients with melanoma, co-mutations in MAP2K1, NF1, and/or EGFR were detected.
DOI:
10.1158/1078-0432.CCR-12-3476
